<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Anges. Inc. — News on 6ix</title>
    <link>https://6ix.com/company/anges-inc</link>
    <description>Latest news and press releases for Anges. Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 04 Mar 2026 12:55:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/anges-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d621bdbeedb30cb6fc2dcd.webp</url>
      <title>Anges. Inc.</title>
      <link>https://6ix.com/company/anges-inc</link>
    </image>
    <item>
      <title>Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients</title>
      <link>https://6ix.com/company/anges-inc/news/vasomune-therapeutics-inc-and-anges-inc-announce-us-fda-clearance-of-investigational-new-drug-ind-application-for-pegevongitide-av-001-treatment-in-resuscitation-of-severely-burned-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/anges-inc/news/vasomune-therapeutics-inc-and-anges-inc-announce-us-fda-clearance-of-investigational-new-drug-ind-application-for-pegevongitide-av-001-treatment-in-resuscitation-of-severely-burned-patients</guid>
      <pubDate>Wed, 04 Mar 2026 12:55:00 GMT</pubDate>
      <description>TORONTO, March 04, 2026--FDA clears IND for Pegevongitide (AV-001), a Tie2 agonist targeting vascular leak, to evaluate acute resuscitation in severe burns.</description>
    </item>
    <item>
      <title>Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications</title>
      <link>https://6ix.com/company/anges-inc/news/vasomune-therapeutics-inc-and-anges-inc-expand-the-scope-of-the-co-development-agreement-to-target-additional-indications</link>
      <guid isPermaLink="true">https://6ix.com/company/anges-inc/news/vasomune-therapeutics-inc-and-anges-inc-expand-the-scope-of-the-co-development-agreement-to-target-additional-indications</guid>
      <pubDate>Tue, 25 Nov 2025 17:00:00 GMT</pubDate>
      <description>TORONTO, November 25, 2025--Vasomune Therapeutics and AnGes Commit to Development of Additional Indications for Pegevongitide (AV-001).</description>
    </item>
  </channel>
</rss>